PMP22

Peripheral myelin protein 22 · Q01453 · PMP22 on Sugi Atlas →

408,764 patent compounds predicted against PMP22, 310,024 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Norepinephrine (SCHEMBL2609)	0.77	4/20
L-Norepinephrine (SCHEMBL2610)	0.77	4/20
Norepinephrine (SCHEMBL2249)	0.74	4/20
Maleic Acid (SCHEMBL3395)	0.36	4/20
Fumaric Acid (SCHEMBL3397)	0.36	4/20
Isoproterenol (SCHEMBL7627)	1.00	3/20
Apomorphine (SCHEMBL8524)	1.00	3/20
Fluoxetine (SCHEMBL8353)	0.97	3/20
Hydroxyprogesterone (SCHEMBL8068)	0.78	3/20
Methyltestosterone (SCHEMBL18657)	0.69	3/20
Oxalic Acid (SCHEMBL3980)	0.63	3/20
Oxalic Acid (SCHEMBL3554)	0.61	3/20
Oxalic Acid (SCHEMBL2525)	0.50	3/20
SCHEMBL19976	0.50	3/20
Oxalic Acid (SCHEMBL3500)	0.49	3/20
SCHEMBL6254	0.44	3/20
SCHEMBL10998	0.40	3/20
Hydrochloric Acid (SCHEMBL3937)	0.38	3/20
Hydrochloric Acid (SCHEMBL2835)	0.37	3/20
Famotidine (SCHEMBL973)	1.00	2/20

Clinical trials — most relevant to PMP22 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
High Dose Ascorbic Acid Treatment of CMT1A	PHASE2/PHASE3	COMPLETED
A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A	PHASE3	COMPLETED
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)	PHASE3	COMPLETED
Ascorbic Acid Treatment in CMT1A Trial (AATIC)	PHASE2	COMPLETED
SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study	PHASE2	COMPLETED
A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1A.	PHASE1	RECRUITING
The Safety and Tolerability of CLZ-2002 in Patients With Charcot-Marie Tooth Disease.	PHASE1	COMPLETED
Central and Peripheral Nervous System Changes as Markers of Disease Progression in Multiple Sclerosis	nan	COMPLETED
Physical Activity Level at Home in CMT1A Patients: Wearable Sensor Assessment	nan	NOT_YET_RECRUITING
Identification of Novel Biomarkers in Early Charcot-Marie-Tooth 1A Disease	nan	RECRUITING
Natural History of the Leukodystrophies	nan	COMPLETED
Genetics of Charcot Marie Tooth (CMT) - Modifiers of CMT1A, New Causes of CMT2	nan	RECRUITING
Biomarkers and Validation of Selected Outcome Measures (CMTBiomarker)	nan	COMPLETED
Impact of Sensory, Motor and Vestibular Deficit on the Postural Stability of CMT Patients	nan	UNKNOWN
Biomarker for Transthyretin-Related Familial Amyloidotic Polyneuropathy (BioTRAP)	nan	WITHDRAWN
The Classification and Cause of Leukodystrophies of Unknown Cause	nan	COMPLETED
A Multi-omic Approach to the Identification of Novel Biomarkers in Early Charcot-Marie-Tooth 1A Disease (CMT1A)	nan	RECRUITING
Disability Severity Scale (DSI) and Hereditary Motor and Sensory Neuropathy Overall Disability Scale (HMSN-R-ODS)	nan	COMPLETED
Longitudinal Biomarkers With Selected Outcome Measures In CMT	nan	RECRUITING
Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others	nan	RECRUITING
Studying Nerve Function and Structure in Charcot-Marie-Tooth Disease, Anti-MAG Neuropathy and CIDP	nan	RECRUITING
Initial Clinical Presentation of Inflammatory Optic Neuritis Associated or Not With Autoantibodies Anti-Myelin-oligodendrocyte-glycoprotein	nan	COMPLETED
Prognostic Value of Biomarkers in Polyneuropathy.	nan	RECRUITING
Productive Value of Sonographic Measurement of Optic Nerve in Transitional Multiple	nan	NOT_YET_RECRUITING
sCD163 as a Potential Biomarker in Guillain- Barré Syndrome	nan	UNKNOWN
Analysis of Pain and Quality of Life in Patients With Charcot-Marie-Tooth Neuropathy (CMT)	nan	COMPLETED
Tools for Therapeutic Evaluation in Charcot-Marie-Tooth Disease Type 1A: Outcome Measures and Biomarkers	nan	ACTIVE_NOT_RECRUITING
Longitudinal Quantitative Neuromuscular MRI in Neuropathic Patients	nan	RECRUITING
Change in MUNIX in Patients With CMT1A Undergoing a Home Ankle Strengthening Program Versus Standard of Care	nan	COMPLETED
Muscle MRI in Charcot Mary Tooth Disease: a Prospective Cohort Study	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PMP22 binder may also engage these)

Protein	Name	Similarity
Q5RAZ3	—	0.999	Q5RAZ3 →
P25094	—	0.993	P25094 →
Q6WL85	—	0.991	Q6WL85 →
Q9TQZ3	—	0.990	Q9TQZ3 →
P16646	—	0.984	P16646 →
Q3ZBV0	—	0.920	Q3ZBV0 →
Q5FVL6	—	0.914	Q5FVL6 →
Q5E9L0	—	0.911	Q5E9L0 →
O95857	—	0.911	O95857 →
Q9Z0S6	—	0.909	Q9Z0S6 →
P55344	—	0.907	P55344 →
Q9D8C2	—	0.907	Q9D8C2 →
B5X3I6	—	0.907	B5X3I6 →
Q7Z7J7	—	0.907	Q7Z7J7 →
P21145	—	0.906	P21145 →
Q6GMK6	—	0.906	Q6GMK6 →
Q5U4E0	—	0.905	Q5U4E0 →
Q5R8E5	—	0.905	Q5R8E5 →
P54825	—	0.903	P54825 →
P56563	—	0.903	P56563 →
Q28296	—	0.903	Q28296 →
Q17R16	—	0.902	Q17R16 →
Q7TSY2	—	0.902	Q7TSY2 →
P78369	—	0.900	P78369 →
P20274	—	0.899	P20274 →
P62957	—	0.899	P62957 →
O35566	—	0.899	O35566 →
Q9QZA6	—	0.898	Q9QZA6 →
Q1RMP9	—	0.898	Q1RMP9 →
Q8IZV2	—	0.897	Q8IZV2 →